Carbamoyl Phosphate Synthetase 1 Deficiency Treatments
Find Carbamoyl Phosphate Synthetase 1 Deficiency Treatments
Medications for Carbamoyl Phosphate Synthetase 1 Deficiency
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Carbamoyl Phosphate Synthetase 1 Deficiency.
Found 1 Approved Drug for Carbamoyl Phosphate Synthetase 1 Deficiency
Phenylbutyrate
Brand Names
Olpruva, Buphenyl, Ravicti, Pheburane
Phenylbutyrate
Brand Names
Olpruva, Buphenyl, Ravicti, Pheburane
Form: Pellet, Tablet, Kit, Powder, Liquid
Method of administration: Oral
FDA approval date: April 30, 1996
Classification: Nitrogen Binding Agent
Glycerol phenylbutyrate oral liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate oral liquid must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). Limitations of Use: Glycerol phenylbutyrate oral liquid is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels. The safety and efficacy of glycerol phenylbutyrate oral liquid for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established. Glycerol phenylbutyrate is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate oral liquid must be used with dietary protein restriction and, in some cases, dietary supplements. ( 1 ) Limitations of Use: Glycerol phenylbutyrate oral liquid is not indicated for treatment of acute hyperammonemia in patients with UCDs. ( 1 ) Safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established. ( 1 )
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances